{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:43:46Z","timestamp":1788241426664,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Fund Project of Anhui Medical University","award":["No. 2019xkj053"],"award-info":[{"award-number":["No. 2019xkj053"]}]},{"name":"The Key Research and Development Plan of Anhui Province, China","award":["No. 201904a07020058"],"award-info":[{"award-number":["No. 201904a07020058"]}]},{"name":"Natural Science Research Project of Provincial Universities","award":["No. KJ2018ZD019"],"award-info":[{"award-number":["No. KJ2018ZD019"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["GrantNo.81670179"],"award-info":[{"award-number":["GrantNo.81670179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the most common types of leukemia in adults with an overall poor prognosis. PD-1 alone or combined with other immune checkpoint blockade is a promising research direction for the treatment of acute leukemia (AL) patients. However, clinical Implications of aberrant PD-1 expression in peripheral CD4+\u2009and CD8+\u2009T lymphocytes of AML and ALL patients in assessing the prognosis of diseases, remains inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the present study, we used flow cytometry to evaluate PD-1 expression on the surface of CD4+\u2009and CD8+\u2009T lymphocytes in the peripheral circulation of AML and ALL patients and its clinical significance. A total of 53 AML patients, 44 ALL patients and 28 healthy controls were enrolled in this study and peripheral blood specimens were detected by flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results indicated that percentages of CD4+\u2009PD1+\u2009and CD8+\u2009PD1+\u2009T lymphocytes in newly diagnosed and non-remission groups were significantly higher than healthy control both in AML and ALL patients. The high level of CD4+\u2009PD1+\u2009and CD8+\u2009PD1+\u2009T lymphocytes were respectively poor prognostic indicators of AML patients and ALL patients but had no significant correlation with most common clinical risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings show that aberrant PD-1 expression correlates with the prognosis of AL patient and may thus serve as poor prognostic indicators. Immunotherapy using PD-1 inhibitors may be a promising strategy for AML and ALL patients with peripheral circulating CD4+\u2009PD1+\u2009and CD8+\u2009PD1+\u2009T lymphocytes positively expressed, respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-023-01352-8","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T13:01:56Z","timestamp":1695819716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical implications of aberrant PD-1 expression for acute leukemia prognosis"],"prefix":"10.1186","volume":"28","author":[{"given":"Yanjie","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanxuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"1352_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1200\/JCO.18.01468","volume":"37","author":"V de Haas","year":"2019","unstructured":"de Haas V, Ismaila N, Advani A, Arber DA, Dabney RS, Patel-Donelly D, et al. Initial diagnostic work-up of acute leukemia: ASCO clinical practice guideline endorsement of the college of American pathologists and American society of hematology guideline. J Clin Oncol. 2019;37:239\u201353.","journal-title":"J Clin Oncol"},{"key":"1352_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59\u201373.","journal-title":"Nat Rev Immunol"},{"key":"1352_CR3","doi-asserted-by":"publisher","first-page":"e12731","DOI":"10.1111\/sji.12731","volume":"88","author":"HG Ljunggren","year":"2018","unstructured":"Ljunggren HG, Jonsson R, Hoglund P. Seminal immunologic discoveries with direct clinical implications: the 2018 nobel prize in physiology or medicine honours discoveries in cancer immunotherapy. Scand J Immunol. 2018;88:e12731.","journal-title":"Scand J Immunol"},{"key":"1352_CR4","doi-asserted-by":"publisher","first-page":"16824","DOI":"10.1002\/jcp.28358","volume":"234","author":"A Salmaninejad","year":"2019","unstructured":"Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, et al. PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol. 2019;234:16824\u201337.","journal-title":"J Cell Physiol"},{"key":"1352_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1084\/jem.165.2.302","volume":"165","author":"MK Jenkins","year":"1987","unstructured":"Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165:302\u201319.","journal-title":"J Exp Med"},{"key":"1352_CR6","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887\u201395.","journal-title":"EMBO J"},{"key":"1352_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/clinchem\/hvaa170","volume":"66","author":"B Hu","year":"2020","unstructured":"Hu B, Sun M, Wang Z, Zheng Y, Cai W, Shi HH, et al. Prognostic value of programmed cell death-ligand 1 expression in tumor-infiltrating lymphocytes and viral load in peripheral blood mononuclear cells for Epstein-Barr virus-positive nasopharyngeal carcinoma. Clin Chem. 2020;66:1219\u201327.","journal-title":"Clin Chem"},{"key":"1352_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u20139.","journal-title":"Nature"},{"key":"1352_CR9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537\u201344.","journal-title":"Blood"},{"key":"1352_CR10","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727\u201342.","journal-title":"Am J Cancer Res"},{"key":"1352_CR11","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","volume":"23","author":"DJ Messenheimer","year":"2017","unstructured":"Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin Cancer Res. 2017;23:6165\u201377.","journal-title":"Clin Cancer Res"},{"key":"1352_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","volume":"24","author":"Y Iwai","year":"2017","unstructured":"Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24:26.","journal-title":"J Biomed Sci"},{"key":"1352_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131:68\u201383.","journal-title":"Blood"},{"key":"1352_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13046-019-1148-5","volume":"38","author":"X Wang","year":"2019","unstructured":"Wang X, Wu WKK, Gao J, Li Z, Dong B, Lin X, et al. Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res CR. 2019;38:140.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"1352_CR15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1158\/2159-8290.CD-16-1184","volume":"7","author":"D Ajona","year":"2017","unstructured":"Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, et al. A combined PD-1\/C5a blockade synergistically protects against lung cancer growth and metastasis. Cancer Discov. 2017;7:694\u2013703.","journal-title":"Cancer Discov"},{"key":"1352_CR16","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270\u20131.","journal-title":"N Engl J Med"},{"key":"1352_CR17","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976\u201386.","journal-title":"N Engl J Med"},{"key":"1352_CR18","doi-asserted-by":"publisher","first-page":"642466","DOI":"10.3389\/fonc.2021.642466","volume":"11","author":"M Wunderlich","year":"2021","unstructured":"Wunderlich M, Manning N, Sexton C, O\u2019Brien E, Byerly L, Stillwell C, et al. PD-1 inhibition enhances blinatumomab response in a UCB\/PDX model of relapsed pediatric B-cell acute lymphoblastic leukemia. Front Oncol. 2021;11:642466.","journal-title":"Front Oncol"},{"key":"1352_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.it.2015.02.007","volume":"36","author":"PJ Siska","year":"2015","unstructured":"Siska PJ, Rathmell JC. T cell metabolic fitness in antitumor immunity. Trends Immunol. 2015;36:257\u201364.","journal-title":"Trends Immunol"},{"key":"1352_CR20","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/bloodadvances.2020003795","volume":"5","author":"M Grioni","year":"2021","unstructured":"Grioni M, Brevi A, Cattaneo E, Rovida A, Bordini J, Bertilaccio MTS, et al. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Emu-TCL1 mice through a CD40L-independent mechanism. Blood Adv. 2021;5:2817\u201328.","journal-title":"Blood Adv"},{"issue":"4","key":"1352_CR21","doi-asserted-by":"publisher","first-page":"e002189","DOI":"10.1136\/jitc-2020-002189","volume":"9","author":"N Bozorgmehr","year":"2021","unstructured":"Bozorgmehr N, Okoye I, Oyegbami O, Xu L, Fontaine A, Cox-Kennett N, et al. Expanded antigen-experienced CD160(+)CD8(+)effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia. J Immunother Cancer. 2021;9(4):e002189.","journal-title":"J Immunother Cancer"},{"key":"1352_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.4251\/wjgo.v12.i11.1255","volume":"12","author":"QJ Sheng","year":"2020","unstructured":"Sheng QJ, Tian WY, Dou XG, Zhang C, Li YW, Han C, et al. Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma. World J Gastrointest Oncol. 2020;12:1255\u201371.","journal-title":"World J Gastrointest Oncol"},{"key":"1352_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fonc.2018.00269","volume":"8","author":"R Shrestha","year":"2018","unstructured":"Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, Dhungel B, et al. Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. Front Oncol. 2018;8:269.","journal-title":"Front Oncol"},{"key":"1352_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3892\/mco.2021.2369","volume":"15","author":"M Saar","year":"2021","unstructured":"Saar M, Narits J, Magi L, Aaspollu H, Vapper A, Kase M, et al. Expression of immune checkpoint PD-1 in non-small cell lung cancer is associated with tumor cell DNA-dependent protein kinase. Mol Clin Oncol. 2021;15:211.","journal-title":"Mol Clin Oncol"},{"key":"1352_CR25","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/s41416-022-01939-8","volume":"127","author":"K Yu","year":"2022","unstructured":"Yu K, Gu Y, Zhang P, Fang H, Cao Y, Wang J, et al. Intratumoral PD-1(+)CD8(+) T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer. Br J Cancer. 2022;127:1709\u201317.","journal-title":"Br J Cancer"},{"key":"1352_CR26","doi-asserted-by":"publisher","first-page":"613007","DOI":"10.3389\/fimmu.2020.613007","volume":"11","author":"F Costa","year":"2020","unstructured":"Costa F, Vescovini R, Marchica V, Storti P, Notarfranchi L, Dalla Palma B, et al. PD-L1\/PD-1 pattern of expression within the bone marrow immune microenvironment in smoldering myeloma and active multiple myeloma patients. Front Immunol. 2020;11:613007.","journal-title":"Front Immunol"},{"key":"1352_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13000-022-01249-w","volume":"17","author":"K Yuan","year":"2022","unstructured":"Yuan K, Wu J, Zhao Y, Lyu S, Zhou Q, Shi F, et al. Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1\/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test. Diagn Pathol. 2022;17:68.","journal-title":"Diagn Pathol"},{"key":"1352_CR28","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.21873\/invivo.12409","volume":"35","author":"MH Kim","year":"2021","unstructured":"Kim MH, Ko GH, Lee JH, Lee JS, Kim DC, Yang JW, et al. PD-1 expression and its correlation with prognosis in clear cell renal cell carcinoma. In Vivo. 2021;35:1549\u201353.","journal-title":"In Vivo"},{"key":"1352_CR29","doi-asserted-by":"publisher","first-page":"e1626653","DOI":"10.1080\/2162402X.2019.1626653","volume":"8","author":"S Kim","year":"2019","unstructured":"Kim S, Nam SJ, Park C, Kwon D, Yim J, Song SG, et al. High tumoral PD-L1 expression and low PD-1(+) or CD8(+) tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. Oncoimmunology. 2019;8:e1626653.","journal-title":"Oncoimmunology"},{"key":"1352_CR30","doi-asserted-by":"publisher","first-page":"33350","DOI":"10.18632\/oncotarget.9061","volume":"7","author":"L Dong","year":"2016","unstructured":"Dong L, Lv H, Li W, Song Z, Li L, Zhou S, et al. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1\/PD-L1 axis activating intracellular AKT\/mTOR pathway in tumor cells. Oncotarget. 2016;7:33350\u201362.","journal-title":"Oncotarget"},{"key":"1352_CR31","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3892\/mco.2014.358","volume":"2","author":"H Sasaki","year":"2014","unstructured":"Sasaki H, Tatemaysu T, Okuda K, Moriyama S, Yano M, Fujii Y. PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. Mol Clin Oncol. 2014;2:1035\u201342.","journal-title":"Mol Clin Oncol"},{"key":"1352_CR32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-013-2581-3","volume":"139","author":"S Muenst","year":"2013","unstructured":"Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139:667\u201376.","journal-title":"Breast Cancer Res Treat"},{"key":"1352_CR33","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s12094-021-02657-y","volume":"23","author":"MA Gamaleldin","year":"2021","unstructured":"Gamaleldin MA, Ghallab OM, Nadwan EA, Abo Elwafa RA. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia. Clin Transl Oncol. 2021;23:2309\u201322.","journal-title":"Clin Transl Oncol"},{"key":"1352_CR34","first-page":"839","volume":"39","author":"B Xia","year":"2018","unstructured":"Xia B, Wu DW, Wang TT, Guo SQ, Wang Y, Yang HL, et al. Expressions and prognostic significance of PTEN and PD-1 protein in patients with classical Hodgkin\u2019s lymphoma. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2018;39:839\u201344.","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"key":"1352_CR35","first-page":"569","volume":"26","author":"S Karakatsanis","year":"2021","unstructured":"Karakatsanis S, Papadatos SS, Syrigos N, Marinos L, Pouliou E, Papanikolaou A. Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: correlation with clinical and pathological findings. J BUON. 2021;26:569\u201379.","journal-title":"J BUON"},{"key":"1352_CR36","doi-asserted-by":"publisher","first-page":"61425","DOI":"10.18632\/oncotarget.18251","volume":"8","author":"ZZ Yang","year":"2017","unstructured":"Yang ZZ, Kim HJ, Villasboas JC, Chen YP, Price-Troska T, Jalali S, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017;8:61425\u201339.","journal-title":"Oncotarget"},{"key":"1352_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2147\/OTT.S289337","volume":"14","author":"M Beck Enemark","year":"2021","unstructured":"Beck Enemark M, Monrad I, Madsen C, Lystlund Lauridsen K, Honore B, Plesner TL, et al. PD-1 expression in pre-treatment follicular lymphoma predicts the risk of subsequent high-grade transformation. Onco Targets Ther. 2021;14:481\u20139.","journal-title":"Onco Targets Ther"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01352-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01352-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01352-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T22:31:39Z","timestamp":1700346699000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01352-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01352-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2137865\/v1","asserted-by":"object"}]},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board Institutional of the Second Hospital of Anhui Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval consent to participate"}},{"value":"The authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}